Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079586 · ClinicalTrials.gov registry record · Phase 3
Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)
A Phase 3 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT00079586 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 150 participants.
The verdict
NCT00079586, a Phase 3 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.
Interventions
- DRUG Heparin
- DRUG Bivalirudin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-04 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079586
The ClinicalTrials.gov registry entry for NCT00079586 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Heparin is the first listed.
NCT00079586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00079586 about?
NCT00079586 is a clinical study titled "Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)". The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.
What is the current status of trial NCT00079586?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2004-04. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00079586?
The interventions under investigation include: Heparin (DRUG), Bivalirudin (DRUG).
Who is sponsoring clinical trial NCT00079586?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.